Using this model, we were able not only to uncouple irAEs from the cancer immunotherapeutic effect (CITE), but also demonstrate that irAE can be avoided by preventing anti-CTLA-4 antibody-induced lysosomal degradation of the CTLA-4 molecules [18,19]. The gene discussed is CTLA4; the disease is cancer.